

Santen Announces Proposed Dividend Change

February 23, 2016, Osaka, Japan -- Santen Pharmaceutical Co., Ltd. announced that its Board of Directors today approved a change in dividends per share for the fiscal year ending March 31, 2016.

1. Reason for Dividend Change

Santen views returning profits to shareholders as one of the important management goals. The company seeks to return profits commensurate with performance, while securing funds for R&D investments, capital expenditures and project development investments.

Taking into consideration earnings and financial condition for the current fiscal year ending March 31, 2016, Santen will propose a year-end dividend of 13 yen, an increase of 1 yen per share from previous forecast, at the company's 104th Annual General Meeting of Shareholders on June 24, 2016. As a result of this proposed increase in year-end dividend, proposed total annual dividends are 25 yen per share.

2. Details of FY2015 Dividend Change (Year ending March 31, 2016)

	Annual dividends (yen)		
	Interim	Year-end	Total
FY2015: Previously announced forecast	-	12.00	24.00
FY2015: Revised forecast	-	13.00	25.00
FY2015: Actual	12.00		
FY2014: Actual	50.00	60.00	110.00

* The company conducted a five-for-one common stock split with an effective date of April 1, 2015. FY2015 dividends per share above are actual figures following the stock split, while FY2014 dividends per share are actual figures before the stock split. If the number of shares following the stock split is applied to FY2014 dividends, the dividends per share would be 12.00 yen (year-end) and 22.00 yen (annual total).

About Santen

As a specialty company dedicated to the ophthalmic field, Santen carries out research, development, sales, and marketing of pharmaceuticals. Santen is the market leader in Japan for prescription ophthalmic pharmaceuticals and sells products in over 50 countries. As a leading company in the field of ophthalmology, Santen aims to contribute to society by supplying valuable products and services to satisfy unmet medical needs. For more details, please see Santen's website (www.santen.com).

Santen Forward-looking Statements

Information provided in this press release contains forward-looking statements. The achievement of these forecasts is subject to risk and uncertainty from various sources. Therefore, please note that the actual results may differ significantly from the forecasts. Business performance and financial conditions are subject to the effects of changes in regulations made by the governments of Japan and other nations concerning medical insurance, drug pricing and other systems, and to fluctuations in market variables such as interest rates and foreign exchange rates.

Contact

Christopher Hohman

General Manager

Corporate Communications Group

Santen Pharmaceutical Co., Ltd.

E-mail: ir@santen.co.jp

Tel: +81-6-4802-9360